Sodium-glucose cotransporter 2 (SGLT2) inhibitors are new antihyperglycemic drugs that target renal proximal tubules and inhibit glucose reabsorption in patients with type 2 diabetes mellitus (T2DM). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.